Trial reportDiabetes, obesity & metabolism2025
Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.
Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03215069. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
Open the trial in the graphWho cites it
3 citing papers in PubMed.
- Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.Diabetes, obesity & metabolism · 2025Trial
- Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs.Current opinion in physiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsWomen with a history of gestational diabetes (GDM) frequently have progressive beta-cell dysfunction, which may result in type 2 diabetes. However, there is a paucity of clinical studies on strategies aiming to preserve beta-cell function in this patient population. This trial evaluated whether empagliflozin can preserve beta-cell function and reduce the prevalence of dysglycemia (prediabetes/diabetes) in women with recent GDM. MATERIALS AND
methodsWe conducted a double-blind, randomized, placebo-controlled trial where 91 women with recent GDM (6-36 months postpartum) were randomized 1:1 to either empagliflozin 10 mg/day or placebo for 48 weeks. Beta-cell function was assessed by Insulin Secretion-Sensitivity Index-2 (ISSI-2) obtained on an oral glucose tolerance test.
resultsThe primary outcome of baseline-adjusted ISSI-2 at 48 weeks was not different between the empagliflozin and placebo group (525 ± 30.4 vs. 560 ± 33.4, p = 0.43). Additional measures of beta-cell function, insulinogenic index/HOMA-IR, and ΔCpep
conclusionsEmpagliflozin had no significant effect on beta-cell function in women with recent GDM. Given the sample size evaluated in this trial, the use of SGLT-2 inhibitors warrants further study to elucidate their potential impact on T2DM prevention in women with previous GDM.
trial registrationClinicaltrials.gov NCT03215069.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.